Jeff P Sharman - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jeff P Sharman

Showing results (71-80 of 75) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 75 results.

The New England Journal of Medicine|December 14, 2021

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.

Blood|September 25, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.

Blood Advances|September 21, 2021

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.

Pageof 8

Search research articles

Showing results (71-80 of 75) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 75 results.

The New England Journal of Medicine|December 14, 2021

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.

Blood|September 25, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.

Blood Advances|September 21, 2021

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.

Pageof 8